Clinical Trials · NCT05691712
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 257
- Start date
- Feb 2023
- Locations
- 25 sites, China
- Primary endpoint
- Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg])